Helus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial Results
Helus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial Results
Unusual Whales
A recent underwritten offering successfully raised $50 million, showcasing robust support from institutional investors and improving the company's financial position. This funding will be allocated towards conducting the second Phase 3 HLP003 trial, known as EMBRACE. The trial is crucial for the potential submission of a New Drug Application to the U.S. FDA by 2028.
